Delivery Order 36F79719D0153-36C26222F0606
Award Date 9/14/22
Potential Completion Date 9/30/22
Potential Value $20K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Pittsburgh, PA 15275, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 22 awarded a $124,840.80 delivery order to Genzyme Corporation under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) for eliglustat/Cerdelga capsules. As the prime contractor, Genzyme Therapeutics Division will deliver the requested pharmaceutical products to a place of performance in Riverwoods, Illinois. No set-aside designation was used for this contract awarded to support...
- Genzyme Corporation, operating through its Sanofi Genzyme division and Genzyme Therapeutics business unit, has been awarded a $17,830.87 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20. The firm fixed price order is for the provision of eliglustat to the agency's Cambridge, Massachusetts facility, with an anticipated completion date of April 19,...
- This is a federal contract award to Genzyme Corporation, doing business as Sanofi Genzyme, for pathology testing services. The $99,200.15 firm-fixed-price delivery order was issued by the U.S. Department of Veterans Affairs (VA) Veterans Health Administration under Genzyme's $659 million Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract. This master contract allows the VA to issue task orders for a broad range of drug and pharmaceutical products over a 5-year period. Genzyme...
- Genzyme Corporation, operating through its Sanofi Genzyme division and Genzyme Therapeutics business unit, has been awarded a $50,142.96 firm fixed price delivery order against the Pharmaceuticals and Drugs GSA Schedule (FSS-61-IB) to provide LEMTRADA for the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 1. Performance will take place in Cambridge, Massachusetts through September 30, 2021. No set-aside designation was used for this award issued...
- Genzyme Corporation, operating through its Sanofi Genzyme division and Genzyme Therapeutics business unit, has been awarded a $71,169.70 firm fixed price delivery order against the Pharmaceuticals and Drugs multiple-award schedule held by its parent company, GSA Schedule FSS-61-IB. The contract calls for Genzyme to provide cancer drugs to support programs run by the Department of Veterans Affairs' Veterans Health Administration Veterans Integrated Service Network 16 located in Cary, North...
- This federal contract award is for the delivery of LEMTRADA INJECTION VIALS to the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA). The contract was awarded to Genzyme Corporation, doing business as Sanofi Genzyme, a global healthcare and pharmaceutical company. It is a firm fixed price delivery order under Genzyme's $659 million Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract with the VA, which allows the VHA to issue task orders for a...
- This is a firm fixed price delivery order awarded by the Department of Veterans Affairs (VA) Veterans Integrated Service Network (VISN) 15 to Genzyme Corporation, doing business as Sanofi Genzyme, under the VA's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract. The order is for the specialty pharmaceutical drug alemtuzumab (Lemtrada) and has a ceiling value of $150,854.30. The contract does not have a set-aside designation. Genzyme Corporation serves as the prime...
- The Department of Veterans Affairs Veterans Health Administration awarded a $11,882.10 delivery order against Genzyme Corporation Sanofi Genzyme Division's Pharmaceuticals and Drugs GSA Schedule contract. Under this firm fixed price order, Genzyme will provide CAPRELSA 100MG to support VHA programs. Performance will take place in Cambridge, Massachusetts over a two week period in November and December 2023. The award utilizes Genzyme's GSA Pharmaceuticals and Drugs Schedule, a multiple award...
- The Department of Veterans Affairs, Veterans Integrated Service Network 20, awarded a $10,105.40 delivery order to Insmed Inc. on March 21, 2025, for an emergency pharmacy order to be performed in Carrollton, Texas. This firm fixed-price delivery order, with an ultimate completion date of September 30, 2025, represents an urgent pharmaceutical supply need within the VA's healthcare network. The award was issued under Insmed's existing Multiple Award Federal Supply Schedule contract (FSS) for...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler located in Park Ridge, Illinois. The contract, valued at $30,046.61, is for the delivery of Cerdelga 84 mg capsules. The award is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA, valued up to $499,999,999, which runs through December 31, 2025. This single-award IDC allows...